Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis
Marco Castellana, Filippo Procino, Rodolfo Sardone, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels
Elvira D’Andrea, Deborah J. Wexler, Seoyoung C. Kim, et al.
JAMA Internal Medicine (2023) Vol. 183, Iss. 3, pp. 242-242
Open Access | Times Cited: 56
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
Guntram Schernthaner, Naim Shehadeh, Ametov As, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 128
Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus
Arash Aghajani Nargesi, Gini Priyadharshini Jeyashanmugaraja, Nihar R. Desai, et al.
Journal of the American Heart Association (2021) Vol. 10, Iss. 13
Open Access | Times Cited: 56
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Yafei Xie, Yujie Wei, Dan Li, et al.
Journal of Cardiovascular Pharmacology (2023) Vol. 81, Iss. 1, pp. 4-14
Closed Access | Times Cited: 34
Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes
Evangelos K. Oikonomou, Marc A. Suchard, Darren K. McGuire, et al.
Diabetes Care (2022) Vol. 45, Iss. 4, pp. 965-974
Open Access | Times Cited: 27
SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
Shih‐Chieh Shao, Liang‐Tseng Kuo, Rong‐Nan Chien, et al.
BMJ Open Diabetes Research & Care (2020) Vol. 8, Iss. 2, pp. e001956-e001956
Open Access | Times Cited: 36
Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
Caiyun Zheng, Meimei Lin, Yan Chen, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 28
Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Shih‐Chieh Shao, Yi-Han Lin, Kai-Cheng Chang, et al.
BMJ Open Diabetes Research & Care (2019) Vol. 7, Iss. 1, pp. e000742-e000742
Open Access | Times Cited: 33
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
João Pedro Ferreira, Subodh Verma, David Fitchett, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 20
Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies
William Hinton, Abdus Samad Ansari, Martin Whyte, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 501-515
Closed Access | Times Cited: 9
A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol
Johan Sundström, Robin Kristófi, Ollie Östlund, et al.
Journal of Diabetes and its Complications (2021) Vol. 35, Iss. 10, pp. 107996-107996
Open Access | Times Cited: 12
The Reasons for the Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects—A Family Doctor Perspective
Tomislav Kurevija, Dunja Šojat, Zvonimir Bosnić, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 6, pp. 1617-1617
Open Access | Times Cited: 1
Interpreting the results of the VERTIS‐CV trial: Is this the end of the “class effect” perspective?
Theocharis Koufakis, Νικόλαος Παπάνας, George Dimitriadis, et al.
Journal of Diabetes (2020) Vol. 12, Iss. 12, pp. 942-945
Open Access | Times Cited: 11
Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study
Tae Won Yi, Mohammad Atiquzzaman, Yuyan Zheng, et al.
Canadian Journal of Kidney Health and Disease (2022) Vol. 9
Open Access | Times Cited: 6
The “Early Treatment” Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique
Giuseppina Russo, Matteo Monami, Gianluca Perseghin, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 5, pp. 1445-1461
Open Access | Times Cited: 7
Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study
Carolina López‐Cano, María Santos, Enric Sánchez, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 4
Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy
Julian W. Sacre, Dianna J. Magliano, Jonathan E. Shaw
Diabetes Care (2022) Vol. 45, Iss. 8, pp. 1900-1906
Open Access | Times Cited: 4
How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real‐world setting?
Dı́dac Mauricio, Jukka Westerbacka, Charlie Nicholls, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 3, pp. 838-843
Open Access | Times Cited: 5
Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes
Veronica Sciannameo, Paola Berchialla, Angelo Avogaro, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 5
The Reasons for Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects – a Family Doctor Perspective: Does Limited Applicability of Clinical Guidelines in Real-Life Practice Matter? A Narrative Review
Tomislav Kurevija, Dunja Šojat, Zvonimir Bosnić, et al.
(2024)
Open Access
SGLT2-gátlók – diabetológián túlmutató előnyökkel rendelkező antihyperglykaemiás szerek
György Jermendy
Cardiologia Hungarica (2021) Vol. 51, Iss. 1, pp. 39-48
Open Access | Times Cited: 3
External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
Lisanne C. A. Smidt, Frank L.J. Visseren, Wendela L. de Ranitz‐Greven, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 1
USE OF SODIUM-GLUCOSE TRANSPORT PROTEIN 2 (SGLT2) INHIBITORS IN DIABETIC KIDNEY DISEASE (DKD)
Rio Manuel Rajagukguk
Journal of Advance Research in Medical & Health Science (ISSN 2208-2425) (2023) Vol. 9, Iss. 4, pp. 46-52
Open Access
A Comparison of Individuals with Diabetes and EMPA-REG Trial Participants: Exploring Aspects of External Validity
Alexander Chaitoff, Joshua D. Niforatos, Jingyi Gong, et al.
Journal of General Internal Medicine (2022) Vol. 37, Iss. 11, pp. 2744-2750
Open Access
Cardiovascular Profile of Patients with Type 2 Diabetes in France Based on REWIND CVOT Inclusion Criteria: A Real-World Retrospective Study
Anne Dib, F. Chartier, Katharina Ihle, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 2, pp. 287-299
Open Access
Page 1 - Next Page

Scroll to top